Hantaviruses are the causative agents of hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome, which are transmitted through inhalation of aerosolized excreta from infected rodents [1] . Among them, HFRS is characterized by renal failure and a high mortality rate [2] . HFRS is endemic in Asia and Europe and is caused by "Old World" hantaviruses, including Hantaan, Seoul, Dobrava-Belgrade, and Puumala viruses. Despite this geographic distinction, outbreaks by Old World hantaviruses have been reported in the United States [3] .
Because no specific treatment has been proven to be effective against hantavirus infection, development of a safe and effective vaccine is of paramount importance [2] . Lee et al developed the first hantavirus vaccine using formalin-inactivated ROK84/105 strain cultured in suckling mice brain [4] . Introduction of the inactivated hantavirus vaccine (IHV) in Korea led to a significant decrease in HFRS incidence [5] . However, there have been some controversies regarding the effectiveness of the vaccine owing to the lack of well-designed clinical trials [6] . As a result, no vaccine against hantavirus has been approved in the United States or Europe [1] .
The Republic of Korea (ROK) Army is at an increased risk of HFRS owing to its geographic location and frequent field exercises. Thus, IHV has been administered to soldiers stationed in high-risk areas since 1993 (Supplementary Figure 1) [7] . Vaccination in this closed population provides an opportunity to examine the effectiveness of IHV. Thus, we conducted a retrospective, matched case-control study to evaluate the vaccine effectiveness (VE) of IHV.
METHODS

Vaccination Policy
Inactivated hantavirus vaccine (IHV) was administered to military personnel stationed in divisions (before 2013) or battalions (since 2013) in which a case of HFRS occurred within the previous 3 years. Vaccination schedules were as follows: 2 primary doses 1 month apart and a booster dose 12 months after the second dose, in accordance with manufacturer guidance.
Identification of Cases and Controls
A matched case-control study for the evaluation of VE was conducted in the ROK Army. HFRS is a notifiable disease; therefore, all cases of HFRS in the military are reported to the Armed Forces Medical Command (AFMC). We retrospectively identified patients with HFRS between January 2011 and February 2017. Case definition by the Korea Centers for Disease Control and Prevention was used. Cases were defined as patients with symptoms compatible with HFRS and either (1) the detection of hantavirus in the blood by polymerase chain reaction, or (2) the presence of hantavirus antibodies confirmed by positive indirect immunofluorescence assay (IFA) with titers ≥1:512, or (3) positive rapid immunochromatography assay. Electronic medical records of the case patients were reviewed for the accuracy of the diagnosis. Demographic information and vaccination status were obtained from the epidemiologic investigation reports.
For each case patient, we enrolled 1 control who sought medical care for non-HFRS notifiable diseases. Controls were matched to case patients by battalion, rank, time of onset, and age; if no exact match could be found, search was expanded with the following priority: (1) stationed at the same or geographically close battalion (at least at the same division); (2) at the same rank (except in sergeants and officers, for whom reasonably close ranks were permitted); (3) nearest time of onset.
Time of onset for controls was defined as their time of presentation to hospital for the non-HFRS notifiable (infectious) diseases.
Collection of Vaccination History
Vaccination history of HFRS cases was obtained from epidemiologic investigation reports archived at the AFMC. They had been recorded by epidemiologic officers at the Army Command or the AFMC shortly after the diagnosis of HFRS according to the Army protocol. Vaccination history was obtained from the vaccination records archived at the battalions as a part of the epidemiologic investigation.
For all controls and 4 case patients whose vaccination records were not recorded in the reports, 2 authors (J. J. and S.-J. K.) contacted battalion medical units to obtain vaccination history from vaccination records archived at the battalions.
Statistical Analysis
VE was estimated as 100% × (1 − odds ratio for vaccination). Because HFRS cases are concentrated in the divisions that are located or regularly train in endemic areas, VE in the high-risk divisions was examined. High-risk divisions were selected as the top 5 divisions in order of case numbers.
Characteristics were compared using χ 2 or t tests, as appropriate. For adjusted VE, we used conditional logistic regression with vaccination status, age, rank, and year and month of onset as the covariates. Statistical analyses were conducted using SPSS Statistics 20 (IBM Corporation, Armonk, New York). This study was approved by the institutional review board of the AFMC, with waiver of informed consent due to the retrospective nature of the study (AFMC-17-IRB-070).
RESULTS
During the study period (January 2011-February 2017), a total of 100 case patients were identified. The annual incidence was 30.16 per 100 000. All patients were male, and the majority (93.0%) were aged <30 years (Table 1) . No statistically significant differences in age, rank, seasonality, and the year of onset between cases and controls were observed. Cases were concentrated in the fall and winter seasons (78%), and most HFRS patients were enlisted soldiers (76%). Cases from the 5 highrisk divisions comprised 59.0% of total cases. Forty-two cases (42%) were diagnosed by polymerase chain reaction (PCR), and the rest were diagnosed based on clinical and serologic criteria. The distribution of diagnoses of controls was as follows: genital condyloma (21%), tuberculosis (16%), pneumonia (14%), malaria (12%), influenza (11%), herpes simplex (6%), mumps (5%), urethritis (5%), scrub typhus (3%), and others (7%).
Among case patients and controls, 27% and 40% of each group were vaccinated with at least 1 dose, respectively (P = .051). Compared to the unvaccinated subjects, the vaccinated subjects were slightly older (24.27 years vs 21.70 years, P = .001) and of higher rank (P = .002; This study demonstrated that IHV was moderately effective against HFRS in young adults. To our knowledge, this is the first study to demonstrate a statistically significant effectiveness of IHV in a real-world setting. Previous studies have shown that while the serologic response after primary doses measured by enzymelinked immunosorbent assay or immunofluorescence assay was high (76%-90%), the proportion of recipients who developed neutralizing antibody, as confirmed by plaque reduction neutralization test (PRNT), was much lower (16%-75%) [6, 8, 9] . These observations raised suspicion over the clinical effectiveness of IHV [5, 6] . In the only field trial that was designed to evaluate the efficacy of IHV, no cases of HFRS were identified among the 1900 subjects who were vaccinated once, whereas 20 cases were reported in the 2000 controls [10] . However, instead of prospective follow-up of the subjects, reports from the notifiable diseases database were used for the identification of HFRS cases in this study. Another study on the protective effectiveness of IHV was reported from the ROK Army in 2004, which shared a method similar to that of the present study [7] . Fifty-seven cases of HFRS were identified over a 2-year period, and the point estimates of VE after 1, 2, and 3 doses were 25%, 46%, and 75%, respectively. However, they failed to demonstrate a statistically significant difference due to a small number of identified cases. Our study, with approximately twice the number of cases, demonstrated VE with a CI narrow enough to draw a clearer conclusion. VEs of the multiple doses were slightly lower than the overall VE in our study, which seems counterintuitive. However, this can be explained by the long time interval (12 months) between the second and third doses, which allowed the vaccine-induced immunity to wane. Most of the subjects in our study who received multiple doses were given 2 doses, and they had significantly longer mean time interval between vaccination and onset compared to that in single-dose recipients (289.8 vs 82.6 days, P = .001; Supplementary Figure 3) . This is in line with a recent PRNT study where the seropositive rate declined to 1.41% at 11 months after the 2 primary doses [6] . Our results, combined with the results from the PRNT study, suggest that the booster (third) dose should be administered earlier than at the currently recommended time.
There are some limitations to this study. A case-control design used in our study cannot eliminate all potential biases such as the difference in risk between 2 groups. However, we selected controls based on stringent criteria, where battalions (geographic location) and rank (duration of exposure) were matched with cases as close as possible. In addition, we tried to adjust for various factors using multiple logistic regression, which yielded comparable results. There is a possibility of information bias, as the sources of information on vaccination status differed between the cases and controls. However, the vaccination history was obtained from records registered at the time of HFRS diagnosis (case) or vaccination (control), which had been recorded independently. The overall adherence to the recommended vaccination schedule seems to be low, probably because timely individual vaccination is often difficult in the military setting. However, overall vaccine coverage would not have affected our case-control design, as the vaccination statuses of individual case-control matches were compared. All cases identified in our study were male; thus, we could not estimate the VE in females. Military service is mandatory only for male citizens in Korea, and therefore all enlisted soldiers are male. The incidence of HFRS and associated mortality rate in Korea are higher in men than in women, which suggests a sex difference in the immune response to hantavirus [11] . Thus, further research is needed to elucidate the effectiveness of IHV in females.
We demonstrated a moderate VE of IHV in young adults residing in a high-risk area. No increase in effectiveness after multiple doses was observed. Further studies are warranted to evaluate the effect of booster doses and the safety of IHV.
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